In this episode of On-Ramp, we sit down with Jason Segal, the mind behind The Armchair Analyst (https://thearmchairanalyst.com/), to break down where the real opportunities are in healthcare investing heading into 2026.
We go beyond the usual biotech hype to unpack what actually moves markets—capital flows, positioning, and incentives. From ASX small caps to US-listed innovators, this is a clear-eyed look at where alpha may exist across biotech, medtech, and life sciences.

